TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Basilea Pharmaceutica Ltd
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea

Basilea announced a USD 30 million milestone payment from Pfizer due to strong European sales of Cresemba®, an antifungal drug. Global Cresemba sales reached USD 652 million in the past 12 months, representing 27% year-on-year growth.

Insights
PFE   positive

Successfully marketing Cresemba and driving sales growth in Europe